| Identification | Back Directory | [Name]
Glycine, (2R)-N-[2-[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, hydrate (1:1) | [CAS]
1633824-78-8 | [Synonyms]
A 3309 hydrate
AZD 7806 hydrate|||AZD 7806 hydrate|||A 3309 hydrate
Glycine, (2R)-N-[2-[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, hydrate (1:1) | [Molecular Formula]
C36H47N3O8S2 | [MOL File]
1633824-78-8.mol | [Molecular Weight]
713.91 |
| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to off-white | [InChIKey]
VARDBGNECHECBX-JODMFMAFNA-N | [SMILES]
O=S1(CC(CN(C2C=CC=CC=2)C2=CC(SC)=C(OCC(=O)N[C@H](C3C=CC=CC=3)C(=O)NCC(=O)O)C=C12)(CCCC)CCCC)=O.O |&1:23,r| |
| Hazard Information | Back Directory | [Uses]
Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research[1]. | [References]
[1] Wong BS, et al. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb; 22(2):277-84. DOI:10.1517/13543784.2013.753056 |
|
|